Study Title
177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan
Study Details
Description:
The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan.
Sponsor:
Ebrahim S Delpassand, MD
Contacts:
Susan Cork (Therapy Coordinator)scork@exceldiagnostics.com
713-781-6200 ext 3203
Nereyda Sauceda (Therapy Coordinator)nsauceda@exceldiagnostics.com
713-781-6200 ext 3246
Government Study Link:
NCT06972628 - Click here to see study onClinicalTrials.gov
Drug Details
Lutetium-177-PSMA-617
Isotope(s):
- LUTETIUM-177
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
Target(s):
- PSMA
Chelator: DOTA
